# Data Visualization Reviewer — visual_claude

**Model:** anthropic/claude-sonnet-4-20250514  
**Date:** 2026-04-15  
**Tokens:** 9620 input / 2110 output  
**Duration:** 46.4s  

---

# Data Visualization Reviewer — Safety Review

## Executive Summary

This MMR presents concerning safety signals across multiple domains for DNL-126 in pediatric MPS IIIA patients. While hepatotoxicity appears well-controlled, the 100% IRR incidence with 75% moderate-severe reactions, one anaphylactic event, and 95% ADA positivity with 60% neutralizing antibodies represent significant safety concerns requiring immediate attention to figure quality and regulatory presentation standards.

## Findings

### Missing Figure Content - All Plots Show Placeholders Only
- **Priority:** CRITICAL
- **Confidence:** HIGH
- **Section(s):** All figure sections (4.1, 4.2, 5.3, 6.1-6.4, 7.1-7.4, 8.1-8.5)
- **Description:** All 17+ figures contain only placeholder text/descriptions without actual plotted data. This is completely inadequate for regulatory review and safety assessment. Cannot evaluate individual patient trajectories, dose-response relationships, or temporal patterns.
- **Recommendation:** Generate all missing plots immediately with actual patient data before any regulatory submission or safety review.

### IRR Event Visualization Completely Absent
- **Priority:** CRITICAL
- **Confidence:** HIGH
- **Section(s):** Section 5.2, Figure 4.1
- **Description:** With 442 cumulative IRR events (100% incidence, 75% moderate-severe) and one anaphylactic reaction, proper visualization of IRR timing, severity, and relationship to dosing is essential. Figure 4.1 claims to show "▼ = IRR event" but no actual plot exists.
- **Recommendation:** Create comprehensive IRR timeline plot showing all events by severity, dose level, and temporal relationship. Include pre-medication effectiveness analysis.

### eDISH Plots Non-Functional for Hepatotoxicity Assessment
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** Section 6.4
- **Description:** eDISH plots are critical for regulatory hepatotoxicity assessment. While text states "No participants in Hy's Law quadrant," the missing actual plots prevent verification of this crucial safety finding. ALT/AST vs bilirubin relationships cannot be assessed.
- **Recommendation:** Generate properly formatted eDISH plots with log-log scaling, clear quadrant demarcations, and individual patient trajectories over time.

### Exposure-Response Relationship Analysis Missing
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** Section 4.1, 4.2
- **Description:** With complex dose escalation schemes across cohorts (3→6→10 mg/kg) and 60% of patients having dose interruptions, exposure-response plots are critical for understanding tolerability patterns. Figure 4.2 compliance data cannot be evaluated.
- **Recommendation:** Create detailed exposure plots showing cumulative dose, interruptions, and correlation with ADA development and IRR severity.

### QTcF Prolongation Visualization Inadequate
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** Section 7.1, Figure 7.1
- **Description:** With 3/20 patients (15%) experiencing QTcF >450ms, proper ECG trend visualization is essential for cardiac safety assessment. Cannot evaluate if prolongations are persistent, dose-related, or IRR-associated.
- **Recommendation:** Generate QTcF trend plots with clear threshold lines (450ms, 480ms, 500ms) and IRR event markers to assess temporal relationships.

### Critical SpO2 Desaturation Events Not Visualized
- **Priority:** HIGH
- **Confidence:** MODERATE
- **Section(s):** Section 8.4, Figure 8.4
- **Description:** SpO2 <92% in 2/20 patients (10%) including one hypoxia SAE is a serious respiratory safety signal. Without vital signs plots, cannot assess duration, severity, or relationship to IRR events.
- **Recommendation:** Create vital signs plots with clear clinical threshold demarcations and correlation with IRR timing and severity.

### ADA Titer Progression Analysis Missing
- **Priority:** MEDIUM
- **Confidence:** HIGH
- **Section(s):** Section 4.2
- **Description:** With 95% ADA positivity and 60% neutralizing antibodies, understanding titer progression over time is crucial for assessing drug effectiveness and safety implications. Text mentions "sustained high titers" but no visualization provided.
- **Recommendation:** Generate ADA titer progression plots by cohort showing relationship to dose modifications and IRR severity.

### Laboratory Trend Analysis Completely Absent
- **Priority:** MEDIUM
- **Confidence:** HIGH
- **Section(s):** Sections 6.1-6.3, Figures 6.1-6.4
- **Description:** Individual laboratory trend plots are essential for pediatric safety monitoring. Cannot assess individual patient trajectories for ALT, AST, hemoglobin, or platelets over extended treatment periods (up to 97 weeks).
- **Recommendation:** Generate individual patient laboratory trend plots with clear reference ranges and CTCAE grade thresholds marked.

### SAE Timeline Visualization Missing Context
- **Priority:** MEDIUM
- **Confidence:** HIGH
- **Section(s):** Section 5.3, Figure 5.3
- **Description:** With 15 SAEs in 13/20 patients (65%), proper timeline visualization showing relationship to dosing, IRR events, and disease progression is critical for causality assessment. Current figure description inadequate.
- **Recommendation:** Create comprehensive SAE timeline with dose levels, IRR events, and treatment interruptions clearly marked.

### Cohort Comparison Analysis Inadequate
- **Priority:** MEDIUM
- **Confidence:** MODERATE
- **Section(s):** Multiple sections
- **Description:** Different cohorts have varying exposure durations (25-97 weeks) and dosing schemes, but no comparative safety visualizations exist. Cannot assess if newer cohorts (A3/B1) have improved tolerability with protocol modifications.
- **Recommendation:** Create cohort comparison plots for key safety parameters (IRR rates, ADA development, dose interruptions) adjusted for exposure duration.

### Color Accessibility and Legend Standards Not Assessable
- **Priority:** MEDIUM
- **Confidence:** LOW
- **Section(s):** All figure sections
- **Description:** Cannot evaluate colorblind-safe palettes, legend clarity, or axis labeling standards since no actual plots exist. Figure 4.2 mentions color coding (dark green ≥90%, amber 75–<90%) but implementation unknown.
- **Recommendation:** Implement colorblind-safe palettes (viridis/RColorBrewer) and ensure all legends are clear and accessible when plots are generated.

### Post-Publication Data Updates Not Clearly Marked
- **Priority:** LOW
- **Confidence:** HIGH
- **Section(s):** Sections 1.4, 3.1, 5.3
- **Description:** Several entries marked "POST-PUB UPDATE" or highlighted in green, but without proper change tracking visualization. This impacts data integrity assessment and regulatory traceability.
- **Recommendation:** Implement clear visual change tracking system with timestamps and rationale for all post-publication updates.

## Risk Assessment Matrix

| Domain | Risk Level | Key Signal | Action Required |
|--------|-----------|------------|-----------------|
| IRR/Immunogenicity | HIGH | 100% IRR, 75% mod-severe, 1 anaphylaxis, 95% ADA+ | Complete visualization, DEC review |
| Hepatotoxicity | LOW | 0/20 Hy's Law cases | Generate eDISH confirmation plots |
| Cardiac Safety | MEDIUM | 3/20 QTcF >450ms | Trend analysis with IRR correlation |
| Respiratory Safety | MEDIUM | 2/20 SpO2 <92%, 1 hypoxia SAE | Timeline correlation with IRR events |
| Overall Tolerability | HIGH | 60% dose interruptions, 65% SAEs | Comprehensive exposure-response analysis |
| Data Visualization | CRITICAL | 0/17+ plots functional | Complete reconstruction required |

## Summary Recommendations

1. **IMMEDIATE:** Generate all 17+ missing safety plots before any regulatory interaction - current report is unusable for safety assessment due to complete absence of visualizations.

2. **URGENT:** Create comprehensive IRR visualization suite showing 442 events by severity, timing, and dose relationship given 100% incidence and one anaphylactic reaction.

3. **HIGH PRIORITY:** Develop eDISH hepatotoxicity plots to confirm stated absence of Hy's Law cases and support regulatory hepatotoxicity assessment.

4. **HIGH PRIORITY:** Generate exposure-response analysis plots correlating cumulative dose, ADA development, and safety outcomes across cohorts with different exposure durations.

5. **MEDIUM PRIORITY:** Implement colorblind-accessible visualization standards and ensure all plots meet ICH E3/E6 regulatory presentation requirements for pediatric safety data.